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Abstract
Background: Publicly-funded drug plans vary in strategies used and policies employed to reduce continually increasing
pharmaceutical expenditures. We systematically reviewed the utilization of cost-sharing strategies and physician-directed
prescribing regulations in publicly-funded formularies within member nations of the Organization of Economic Cooperation
and Development (OECD).
Methods & Findings: Using the OECD nations as the sampling frame, a search for cost-sharing strategies and physician-
directed prescribing regulations was done using published and grey literature. Collected data was verified by a system
expert within the prescription drug insurance plan in each country, to ensure the accuracy of key data elements across
plans. Significant variation in the use of cost-sharing mechanisms was seen. Copayments were the most commonly used
cost-containment measure, though their use and amount varied for those with certain conditions, most often chronic
diseases (in 17 countries), and by socio-economic status (either income or employment status), or with age (in 15 countries).
Caps and deductibles were only used by five systems. Drug cost-containment strategies targeting physicians were also
identified in 24 countries, including guideline-based prescribing, prescription monitoring and incentive structures.
Conclusions: There was variable use of cost-containment strategies to limit pharmaceutical expenditures in publicly funded
formularies within OECD countries. Further research is needed to determine the best approach to constrain costs while
maintaining access to pharmaceutical drugs.
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Introduction
Pharmaceutical expenditures account for between 7% and 34%
of total health spending across the 34 Organization of Economic
Cooperation and Development (OECD) countries [1] and are
growing faster than the gross national product in all European
countries [2]. Given the increased use of drugs, and as new and
more expensive drugs become available, the financial pressure on
both individuals and publicly-funded drug plans continues to
increase [3]. Publicly-funded drug plans are often included as part
of public health insurance as many medications are considered
necessary to maintain or improve health, and may not be
affordable to many people. However, prescription drug insurance
needs to balance the goals of equity and access while acknowl-
edging that budgets are limited [4].
Given differences in socio-demographic characteristics, geo-
political systems, and the mandates of the agencies that offer
prescription drug insurance, publicly-funded outpatient prescrip-
tion drug insurance plans have evolved in different ways across
different countries leading to variations in the types of citizens
covered, cost-sharing strategies used and policies employed to
reduce expenditures within publicly funded drug plans. These
differences can be thought of as tradeoffs. Higher patient
copayments can reduce patient consumption, and possibly
encourage patients to use care more efficiently while generating
revenue to reduce insurer costs; however, no copayment removes
the financial disincentive to forgo care, but risks an inappropriate
consumption of pharmaceuticals. Copayments can therefore be
viewed as inequitable, as they create a barrier to seek necessary
medications to maintain health, particularly in those with a lower
socioeconomic status.
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Previous reports have noted differences across countries in
access to prescription drug insurance, including reimbursement
available for selected groups based on age, disease severity or
income status [5–7], or copayment levels [5,8,9]. This study is part
of a larger initiative exploring how the different characteristics of
publicly-funded prescription drug insurance plans across OECD
countries correlate with differences in appropriate access to drugs
and drug expenditure, with the goal of informing drug policy. In
this article, we report the findings of a systematic review of the
utilization of cost-sharing strategies, including the use of copay-
ments, deductibles, premiums, and of physician-directed prescrib-
ing regulations in OECD countries. We also highlight unique
features of selected systems to showcase some of the innovative
approaches to cost sharing along with strategies aimed to reduce
inappropriate drug prescribing that could be adapted and adopted
elsewhere.
Methods
Study sample
The OECD nations formed the sampling frame, as they include
both developed and emerging nations from Europe, North
America, Latin America and Australasia, representing countries
with varied sociocultural characteristics, budgetary restrictions and
healthcare systems. Only OECD countries that offered publicly
funded health care along with a publicly funded outpatient
pharmaceutical insurance system to at least a portion of its citizens
were included. Publicly funded drug insurance systems that
focused solely on inpatient drugs or drugs for a specific clinical
condition, such as cancer, were excluded.
Database search strategy
Two reviewers searched the following electronic databases, from
inception until March 2012: MEDLINE, EMBASE, PubMed. In
brief, the key terms included the terms: drug costs, formularies,
prescription drugs, reimbursement mechanisms, and insurance. The search
was developed in consultation with an experienced librarian
(Figure S1 for full details). A secondary search was undertaken in
the grey literature, focusing on, but not limited to, the various drug
reimbursement agency websites. Only the most recent information
for each country was retained. Data collection from public
documents commenced March 2011 and finished in September
2012.
Website search strategy
Concurrently with the database searching, we carried out a
search of relevant drug agency websites, publicly-funded health
insurers, and relevant terms using Google. We searched websites
in a systematic manner, first using the site map to identify research
and/or publication links and then using the website’s search
engine to search relevant terms. For all websites, we searched the
terms: reimbursement, pharmaceutical, committee, and formulary. Logs
were kept of websites searched, with links to relevant pages saved.
As the majority of the data came from the grey literature, we
identified a person familiar with the process through which new
prescription drugs are evaluated for inclusion within the formulary
within each jurisdiction (‘‘system expert’’) and verified the
accuracy of subjective data elements abstracted. System experts
were identified through peer-reviewed publications, agency
websites, or appropriate contacts of the research team. A table
of the collected data was e-mailed to the system expert, who was
asked to confirm its accuracy or clarify any discrepancies. The
experts were invited to enter additional comments and provided
information between January and September 2012.
Variable definition
Recognizing that countries may define cost-sharing strategies
differently, we define our terminology as follows:
– Cap. A limit below which a patient does not pay or has
reduced payments for prescriptions. After the cap is reached,
payment is required by the patient. All caps are assumed to be
annual unless otherwise specified.
– Fixed copayment. A system where a patient pays a fixed, or
set, amount per drug or per prescription.
– Percentage copayment. A system where a patient pays a set
percentage of the amount per drug or per prescription
– Tiered copayments. A structure where certain drugs (either
generic, particularly effective or cost-effective brand name
drugs) are assigned a lower copayment (first tier), with non-
preferred brand drugs assigned a higher copayment (second
tier). A third tier, with an even higher copayment, may be
assigned to less preferred brand drugs.
– Deductible. A limit up to which a patient pays the full cost of
the drug. After the deductible is reached, the patient either
does not pay or has reduced payments for prescriptions. All
deductibles are assumed to be annual unless otherwise
specified.
– Premium. A fixed amount, not related to the number of
prescriptions, that a beneficiary must pay to be eligible for
prescription drug insurance.
– Maximum out-of-pocket limit. A limit that is set as a fixed
dollar amount or as a percentage of income after which the
insurer pays 100% of the drugs. Copayments are in place prior
to the limit being reached. All maximum out-of-pocket limits
are assumed to be annual unless otherwise specified.
Data abstraction
Data was gathered on the characteristics of healthcare systems,
the details relating to outpatient pharmaceutical insurance within
each country, and the specifics of the pharmaceutical reimburse-
ment decision-making systems. All data were extracted in
duplicate by two members of the research team (LB and FC)
with disagreements resolved by consensus. A kappa statistic for
agreement between reviewers was calculated for each country, and
agreement was between 0.8 and 1.0, for all data collection
elements. Country experts were identified through peer-reviewed
publications, agency websites, or appropriate contacts of the
research team. A table of the collected data was e-mailed to the
country expert, who was asked to confirm its accuracy or clarify
any discrepancies. The experts were invited to enter additional
comments. A list of the ‘‘country experts’’ is available upon
request.
Data synthesis
A description of the data collected on use and structure of cost-
sharing strategies (copayments, caps and deductibles) (as defined
above), as well as physician-directed prescribing regulations
(compulsory or non-compulsory prescription guidelines, monitor-
ing and comparison of prescription patterns and volumes,
incentives and sanctions) are presented separately for each
country. In addition to a tabular summary, a qualitative summary
is given of three unique strategies directed at physician prescribing
behavior.
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Results
The search yielded 2,466 citations, 41 of which were selected for
full-text review. Of these, 5 studies, met our inclusion criteria of
addressing cost-sharing mechanisms in publicly-funded health care
systems. Through searching the grey literature, 98 reports were
identified along with prescription drug insurance websites (Table
S1)
Availability of publicly funded prescription drug
insurance
Of the 34 OECD countries, one country (Chile) was excluded as
there is no publicly-funded prescription drug insurance provided
in the country. Given the unique characteristics of health care
systems in Ireland, Mexico and the U.S., data were collected for
select national publicly-funded insurance plans: General Medical
Services Scheme in Ireland for those over 70 and those with lower
income; Seguro Popular in Mexico for those with low income; and
Part D Medicare in the U.S, for those over the age of 65 as they
cover a large proportion of the population. As Canada and Israel
have several drug insurance plans, none of which are available at a
national level to all citizens, we provide an overview of system
characteristics. Further, we included both England and Scotland
from the United Kingdom as the characteristics of prescription
drug insurance varies between the two systems. Thus, 34 systems
were included in the final analysis: Australia, Austria, Belgium,
Canada, Czech Republic, Denmark, England, Estonia, Finland,
France, Germany, Greece, Hungary, Iceland, Ireland- General
Medical Services Scheme, Israel, Italy, Japan, Luxembourg,
Mexico- Seguro Popular, Netherlands, New Zealand, Norway,
Poland, Portugal, Scotland, Slovakia, Slovenia, South Korea,
Spain, Sweden, Switzerland, Turkey, and United States (US)- Part
D Medicare.
Five countries included in this review do not provide universal
prescription drug insurance for all citizens, with or without a
premium: Canada, Estonia, Israel, Mexico and the United States.
Prescription drug insurance in Estonia varies by age and
employment status; however, over 95% of the population is
covered by prescription drug insurance. Seguro Popular in Mexico
covers those who are unable to get private insurance due to lower
income and is provided with no premiums by the government.
Medicare part D in the United States is available to all US citizens
aged 65 or over. Those on disability or with end-stage renal
disease on dialysis under the age of 65 are also eligible. In Canada
and Israel, plans vary by region of the country or by health fund,
respectively, and may be subject to a premium.
Cost sharing policies within publicly funded prescription
drug insurance systems
The use of cost-sharing mechanisms varied significantly
(Table I). Seventeen countries (Belgium, Czech Republic, Den-
mark, England, Estonia, Greece, Finland, Hungary, Italy,
Luxembourg, New Zealand, Norway, Poland, Slovenia, South
Korea, Spain, and Turkey) had reduced or no copayments for
those with certain conditions, most often chronic diseases, though
the type of chronic conditions varied from system to system. Five
countries had copayments which varied depending on the type of
drug or its indication for use. In Portugal, the copayment for drugs
was dependent on the deemed essential nature of the pharma-
ceutical or class of medications, while in Greece and Sweden, there
are no copayments explicitly for insulin. In Iceland and Slovakia,
all pharmaceuticals deemed vital by the agency are reimbursed in
full. Finally, copayments varied by socio-economic status, either
income or employment status, or with age in 15 countries:
Australia, Belgium, Czech Republic, England, Estonia, Greece,
Hungary, Italy, Japan, New Zealand, Norway, Slovenia, South
Korea, Spain, and Turkey. Copayments varied as either fixed,
percentage, or a combination of both, with some systems placing a
maximum dollar value on the percentage. In the Netherlands, the
copayment was the difference between the retail price and the
reference price, set by the agency. Thirteen countries employed a
maximum out-of-pocket limit for the beneficiary. These limits
were either fixed (Australia, Finland, Japan, Norway, South
Korea), varied by the annual income of the patient (Austria,
Germany, Luxembourg), age (Czech Republic, Switzerland), or
presence of chronic conditions (Belgium, Denmark, Germany).
Though there was no set maximum out-of-pocket limit for the
Medicare system in the US, depending on the specifics of the plan,
the copayment reduces to less than 5% once a threshold is
reached.
Patient and system-level restrictions
Throughout the included OECD countries, only one system
employed a premium as a mechanism to fund the prescription
drug insurance plan: Medicare part D, where premiums vary
according to plan and income. Only one country employed a
system of caps; Switzerland allowed reduced copayments for brand
name drugs, up to a cap of 933 CHF, after which patients were
responsible to pay for 100% of the prescription. This cap did not
apply to generic drugs. Four systems in the OECD used a
deductible: Denmark, the Netherlands, Sweden, and Medicare
part D. In the Netherlands, there is no copayment or reimburse-
ment under 170 euros of annual expenses. In Denmark and
Sweden, the percentage copayment decreases throughout the year
based on consumption. The amount of the deductible for
Medicare part D varies according to plan and ranges from no
deductible to 325 USD.
Volume control measures aimed at physicians
Cost-containment strategies targeting physician prescribing
were seen in several jurisdictions. Sixteen countries enforced
guideline-based prescribing, either compulsory or non-compulsory
(Table II). Physician prescription patterns and volume were
monitored in nineteen countries, and in several of these countries,
the patterns and volume of physician prescribing were bench-
marked against others (Austria, Belgium, Denmark, England,
Estonia, Finland, Hungary, and Slovenia). Incentive structures in
the form of rewards were used in four countries (Austria, Belgium,
England, and Spain) and sanctions for over-prescribing were seen
in three countries (Austria, Belgium, and Luxembourg).
Strategies to change physician-prescribing practice
Though strategies to change physician-prescribing practice were
seen in several countries, the following are three unique system
cases that utilize several physician-directed strategies aimed at
reducing costs through rational prescribing. In Austria, physician’s
prescription patterns are monitored, and volume is benchmarked
against others, to ensure that the most cost-effective drug is chosen
when a physician has several similar therapeutic options. In the
case of serious discrepancies, doctors may be forced to pay back
the difference between the price of the prescribed product and the
average prescribed price [10]. This is very rare and is usually
solved through arbitration. In Belgium, consensus meetings are
held at least twice a year to formulate recommendations for all
prescribing physicians. Agreements exist between some insurers
and doctors that allow a bonus to be paid to the doctor if
prescriptions for antibiotics, for example, fall below a certain
threshold. Doctors are obliged to prescribe a certain amount of
International Cost-Sharing Strategies
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Table 1. Use of cost-sharing and cost-containment policies within included OECD countries.
Copayments Sources*
Country
Use of
copayment
Vary by
condition
Vary by
type of
drug
Vary by socio-
economic state
Fixed or
percentage
Maximum
out –of-pocket
limit (MOPL) Cap Deductible
Australia Yes No No Yes Fixed Fixed, dependent
on type of patient
No No [9,34–37]
Austria Yes No No No Fixed 2% of annual
income
No No [10,38–40]
Belgium Yes Yes No Yes Percentage Dependent on
type of patient
No No [41–45]
Canada Varies by plan No No Varies by plan Varies by plan Varies by plan Varies by plan Varies by plan [7,46–51]
Czech
Republic
Yes Yes No Yes Fixed Set at 200J; for
children under 18
and adults over
65, set at 100J
No No [52,53]
Denmark Yes Yes No No Both Set at 406J for
chronically ill
patients
No Yes [54,55]
England Yes Yes No Yes Fixed No No No [45,56–59]
Estonia Yes Yes No Yes Both No No No [60,61]
Finland Yes Yes No No Percentage Set at 672J;
subsequent costs
are reimbursed
in full after a fixed
1.50J copayment
No No [62–64]
France Yes No No No Both No No No [45,65–67]
Germany Yes No No No Both Set at 2% of net
income; 1% of
net income for
chronically ill
patients
No No [45,68–72]
Greece Yes Yes Yes Yes Percentage No No No [73,74]
Hungary Yes Yes No Yes Percentage No No No [75,76]
Iceland Yes No Yes No Percentage No No No [77]
Ireland** Yes No No No Fixed 19.50J per month
per family
No No [78–83]
Israel Varies by plan Varies by plan Varies by
plan
Varies by plan Varies by plan Varies by plan No No [84,85]
Italy Yes Yes No Yes Fixed No No No [45,86–88]
Japan Yes No No Yes Percentage Set at 80,000
yen monthly
No No [89–93]
Luxembourg Yes Yes No No Percentage 2.5% of net
income
No No [94,95]
Mexico+ No No No No [96,97]
Netherlands Yes No No No Difference
between
reference price
and retail
No No Yes [45,98]
New Zealand Yes Yes No Yes Fixed No No No [35,99–101]
Norway Yes Yes No Yes Both Set at 216J and
63J per
prescription
No No [102]
Poland Yes Yes No No Both No No No [103–105]
Portugal Yes No Yes No Percentage No No No [106,107]
Scotland No No No [57]
Slovakia Yes No Yes No Both No No No [108,109]
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lower priced pharmaceuticals, defined as prescribing by active
ingredient; by generic brand name; or prescribing originators
priced at the reference price level. If a doctor fails to attain the
national minimum of these lower priced pharmaceuticals, which
was set at 27% of all prescriptions in 2008, prescriptions are
monitored for a further six months. If no improvement is seen by
the end of this period, the doctor is liable for a fine of between
J1,000 and J5,000. This has doubled the number of lower priced
pharmaceuticals prescribed, from 2004 to 2005 [11]. Finland uses
a computer program for rational prescribing, informed by the
information on effectiveness and cost-effectiveness submitted by
manufacturers to the drug reimbursement agency, facilitates
physicians choosing the recommended drug based on efficiency,
safety, and patient appropriateness. Each year, doctors receive a
summary of their prescriptions and costs from the prescribing
system, including data on the number of prescriptions, distribution
of patients’ age and gender, and average cost per prescription, to
other doctors in the same region. The Finnish Medical Society has
issued national clinical treatment guidelines for common diseases,
with the most recent edition including economic information.
Discussion
Publicly-funded prescription drug plans are constantly evolving.
The majority of countries included in this review, however,
utilized some form of cost-sharing strategy, most commonly
copayments, though the magnitude of copayment varied across
countries, and within countries by socioeconomic class, age or
presence of chronic condition. In addition, we noted that several
countries used unique cost-containment features including varying
levels of copayment for generic versus brand name drugs and a
copayment that is calculated based on the difference between the
retail price and the reference price. Strategies aimed at encour-
aging appropriate prescribing by physicians were noted in several
countries, in various forms, as an effort to reduce volume and/or
expenditures.
The issue of cost constraint within health systems has become
more relevant since the recent 2008 financial crisis. Indeed, during
the recent financial crisis, a study noted that 89 pharmaceutical
policy changes across 23 countries, many of which were OECD,
were implemented [12]. Though these changes may not all be
directly related to the financial crisis, it highlights the desire of
publicly-funded drug plans to shift the burden of increasing
expenditures onto the patient. Our review suggests that countries
have different approaches to limiting expenditures for their
publicly-funded drug plans and place different priorities on who
should be able to access prescription drug insurance, and at what
cost. These decisions, as expected, have impacts on equity in any
given system. The relative value of each system rests on the
principles of each society and needs to be evaluated in the context
of the trade-offs that copayments offer.
Copayments provide significant opportunities in a prescription
drug insurance plan to maximize their budget: one study found
that doubling a patient’s co-payment in a given plan, regardless of
the type of co-payment, reduces average annual drug spending by
one-third [13]. Increasing co-payments, however, has been shown
to decrease drug usage in an effort by the patient to maintain their
overall costs; of concern, patients are unlikely to reduce
consumption of only less effective medications. One study found
that for every $10 increase in co-payments, average compliance
fell by 5 percentage points and that lower compliance resulted in
greater use of other more expensive medical services [14]. The
impact on clinical outcomes of potential decreased drug use has
been examined previously, though the evidence is conflicting. The
RAND Health Insurance Experiment examined the effect of
copayments on health outcomes and while they noted no evidence
that copayments affected clinical outcomes for patients overall,
they noted that in people with lower incomes the presence of a
Table 1. Cont.
Copayments Sources*
Country
Use of
copayment
Vary by
condition
Vary by
type of
drug
Vary by socio-
economic state
Fixed or
percentage
Maximum
out –of-pocket
limit (MOPL) Cap Deductible
Slovenia Yes Yes No Yes Percentage No No No [105,110]
South Korea Yes Yes No Yes Percentage Set at 2, 3 or 4
million KRW
depending on
health insurance
plan
No No [93,111–116]
Spain Yes Yes No Yes Percentage No No No [45,117,118]
Sweden Yes No Yes No Percentage No No Yes [22,119–123]
Switzerland Yes No No No Percentage Set at 700 CHF
for adults and
350 CHF for
children
Yes Yes [124,125]
Turkey Yes Yes No Yes Percentage No No No [96,105,126]
US++ Varies No No No Copayment
reduces to 5%
after limit
Varies by plan.
Step therapy,
prior
authorization and
cost tiers
[127]
* in addition to system experts and agency websites.
** General Medical Services Scheme.
+Seguro Popular plan.
++Medicare.
doi:10.1371/journal.pone.0090434.t001
International Cost-Sharing Strategies
PLOS ONE | www.plosone.org 5 March 2014 | Volume 9 | Issue 3 | e90434
T
a
b
le
2
.
St
ra
te
g
ie
s
to
in
cr
e
as
e
ap
p
ro
p
ri
at
e
p
re
sc
ri
b
in
g
.
C
o
u
n
tr
y
C
o
m
p
u
ls
o
ry
p
re
sc
ri
p
ti
o
n
g
u
id
e
li
n
e
s*
N
o
n
-c
o
m
p
u
ls
o
ry
p
re
sc
ri
p
ti
o
n
g
u
id
e
li
n
e
s
P
re
sc
ri
p
ti
o
n
p
a
tt
e
rn
a
n
d
v
o
lu
m
e
m
o
n
it
o
re
d
P
re
sc
ri
p
ti
o
n
p
a
tt
e
rn
a
n
d
v
o
lu
m
e
co
m
p
a
re
d
to
o
th
e
rs
In
ce
n
ti
v
e
s
S
a
n
ct
io
n
s
O
th
e
r
A
u
st
ra
lia
X
X
X
X
X
X
A
u
st
ri
a
X
X
3
3
3
3
B
e
lg
iu
m
X
3
3
3
3
3
C
an
ad
a
X
X
X
X
X
X
N
o
re
g
u
la
ti
o
n
o
f
p
re
sc
ri
b
in
g
C
ze
ch
R
e
p
u
b
lic
X
X
X
X
X
X
O
n
ly
sp
e
ci
al
is
ts
ca
n
p
re
sc
ri
b
e
n
e
w
an
d
m
o
re
e
xp
e
n
si
ve
p
h
ar
m
ac
e
u
ti
ca
ls
D
e
n
m
ar
k
X
3
3
3
X
X
In
te
ra
ct
iv
e
d
at
ab
as
e
to
fa
ci
lit
at
e
se
lf
-m
o
n
it
o
ri
n
g
En
g
la
n
d
X
3
3
3
3
X
Es
to
n
ia
3
X
3
3
X
X
O
n
ly
o
n
e
p
h
ar
m
ac
e
u
ti
ca
l
p
e
r
p
re
sc
ri
p
ti
o
n
Fi
n
la
n
d
X
3
3
3
X
X
R
at
io
n
al
p
re
sc
ri
b
in
g
p
ro
g
ra
m
fo
r
d
o
ct
o
rs
Fr
an
ce
3
X
3
X
X
X
G
e
rm
an
y
3
X
X
X
X
X
G
re
e
ce
X
X
X
X
X
X
H
u
n
g
ar
y
X
X
3
3
X
X
Ic
e
la
n
d
X
X
X
X
X
X
Ir
e
la
n
d
X
3
X
X
X
X
C
e
rt
ai
n
in
su
ra
n
ce
sc
h
e
m
e
s
h
av
e
th
e
ri
g
h
t
to
in
fl
u
e
n
ce
th
e
p
re
sc
ri
b
in
g
o
f
d
o
ct
o
rs
Is
ra
e
l
X
X
3
X
X
X
It
al
y
3
X
X
X
X
X
Ja
p
an
X
X
3
X
X
X
Lu
xe
m
b
o
u
rg
X
3
3
X
X
3
Sa
n
ct
io
n
s
ar
e
ra
re
ly
ap
p
lie
d
M
e
xi
co
X
X
X
X
X
X
N
e
th
e
rl
an
d
s
X
3
3
X
X
X
N
e
w
Z
e
al
an
d
X
X
X
X
X
X
N
o
rw
ay
X
X
3
X
X
X
P
o
la
n
d
X
X
X
X
X
X
P
o
rt
u
g
al
X
3
X
X
X
X
Sc
o
tl
an
d
X
3
3
X
X
X
International Cost-Sharing Strategies
PLOS ONE | www.plosone.org 6 March 2014 | Volume 9 | Issue 3 | e90434
T
a
b
le
2
.
C
o
n
t.
C
o
u
n
tr
y
C
o
m
p
u
ls
o
ry
p
re
sc
ri
p
ti
o
n
g
u
id
e
li
n
e
s*
N
o
n
-c
o
m
p
u
ls
o
ry
p
re
sc
ri
p
ti
o
n
g
u
id
e
li
n
e
s
P
re
sc
ri
p
ti
o
n
p
a
tt
e
rn
a
n
d
v
o
lu
m
e
m
o
n
it
o
re
d
P
re
sc
ri
p
ti
o
n
p
a
tt
e
rn
a
n
d
v
o
lu
m
e
co
m
p
a
re
d
to
o
th
e
rs
In
ce
n
ti
v
e
s
S
a
n
ct
io
n
s
O
th
e
r
Sl
o
va
ki
a
3
X
3
X
X
X
In
su
ra
n
ce
co
m
p
an
ie
s
m
o
n
it
o
r
th
e
ra
ti
o
o
f
p
re
sc
ri
b
e
d
o
ri
g
in
al
s
ve
rs
u
s
g
e
n
e
ri
cs
fo
r
co
n
tr
ac
t
d
o
ct
o
rs
Sl
o
ve
n
ia
X
X
3
3
X
X
O
n
ly
o
n
e
p
h
ar
m
ac
e
u
ti
ca
l
p
e
r
p
re
sc
ri
p
ti
o
n
,
fo
r
a
o
n
e
-m
o
n
th
su
p
p
ly
So
u
th
K
o
re
a
X
X
3
X
X
X
Sp
ai
n
X
X
3
X
3
X
B
o
n
u
se
s
to
p
h
ys
ic
ia
n
s
if
p
h
ar
m
ac
e
u
ti
ca
l
e
xp
e
n
d
it
u
re
d
o
e
s
n
o
t
e
xc
e
e
d
fo
re
ca
st
e
d
g
ro
w
th
at
th
e
re
g
io
n
al
le
ve
l
Sw
e
d
e
n
X
3
3
X
X
X
C
o
u
n
ty
co
u
n
ci
ls
ar
e
re
sp
o
n
si
b
le
fo
r
p
re
sc
ri
b
in
g
p
o
lic
ie
s
in
th
e
ir
re
sp
e
ct
iv
e
re
g
io
n
Sw
it
ze
rl
an
d
X
X
X
X
X
X
N
o
re
g
u
la
ti
o
n
o
f
p
re
sc
ri
b
in
g
T
u
rk
e
y
3
X
X
X
X
X
G
u
id
e
lin
e
s
fo
r
n
u
m
b
e
r
o
f
it
e
m
s,
d
o
se
an
d
tr
e
at
m
e
n
t
ti
m
e
as
w
e
ll
U
S
M
e
d
ic
ar
e
X
X
X
X
X
X
St
e
p
th
e
ra
p
y
an
d
p
ri
o
r
au
th
o
ri
za
ti
o
n
u
se
d
3
=
ye
s;
X
=
n
o
.
*
m
ay
n
o
t
b
e
av
ai
la
b
le
fo
r
al
l
co
n
d
it
io
n
s.
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
o
n
e
.0
0
9
0
4
3
4
.t
0
0
2
International Cost-Sharing Strategies
PLOS ONE | www.plosone.org 7 March 2014 | Volume 9 | Issue 3 | e90434
copayment was a barrier to seeking care [15]. The RAND study
was conducted in the early 1980s, however, before medications
became a cornerstone of treating many chronic conditions. Since
then, studies have noted similar findings for the elderly, and low-
income individuals, where the introduction of a cost-sharing policy
decreased the use of essential drugs and increased the incidence of
serious adverse events [16]
Some systems attempted to mitigate the potential clinical impact
of copayments by differentially lowering co-payments for patients
with specific chronic conditions or for certain medication classes.
This strategy has little evidence to support or refute its utility. One
study showed that in chronically ill patients, doubling co-payments
from $5 to $10 caused greater delays in starting treatment [17].
Another study noted that in a high risk group of US Veteran’s
Administration patients with coronary heart disease, increasing
copayment by $5 per prescription resulted in a 30–40% lower
adjusted odds of adherence, across a variety of measures, for
patients who were subject to copay [18]. Finally, other studies have
noted that lower copayments have also been noted to improve
adherence while not affecting overall expenditure in people with
chronic conditions [19–25].
Placing a cap on the amount of benefit a patient can receive
during a given time period was another cost-sharing strategy,
though this was only used by one country (Switzerland) and in
certain plans in Canada and the United States. Though the
evidence is limited, one study found that among the chronically ill,
patients who had reached their benefit cap are more likely to stop
taking their medications than those who haven’t [26]. Further, of
those who stopped their medications, only a minority resumed
therapy in the first three months after their coverage returned. The
impact of this on clinical outcomes and overall costs is uncertain
[26].
Targeting the prescribing practices of physicians is another
strategy that health care payers have used to reduce excessive
prescribing. Since decisions about which medications are needed
for which conditions are generally made by physicians, it might be
argued that a higher burden for reducing expenditures should be
placed on the healthcare provider through the use of incentives
[27]. We noted several strategies aimed at physician prescribing
across different OECD countries in an effort to engage physicians
and transfer some of the responsibility for cost-containment
measures. France implemented mandatory practice guidelines,
including prescribing, in 1994 [28]. Though the sanctions have
since been removed since implementation, the implementation of
the guidelines did result in an overall net reduction in drug
expenditure. However, because of the lack of sanctions imposed
on physicians, compliance is low, and the effectiveness of this
policy is uncertain [29]. In 2004, the Norwegian Medicines
Agency made thiazides the only reimbursed drug class for
uncomplicated hypertension, in an effort to reduce expenditures
[30]. The introduction of the new rule significantly changed
prescription practices, with no change in clinical outcomes.
However, the expected decrease in drug expenditures was not
observed. In 2009, Finland began to implement a system that
provides guidelines (which consider both effectiveness and cost-
effectiveness) electronically to physicians to optimize use of
medications [31]. However, no evaluation on the efficacy of these
electronic guidelines or the strategies seen in other countries has
been conducted. A careful evaluation of these strategies, and their
impact on clinical outcomes, is needed to inform health systems
about the impact of such strategies.
We were unable to infer the relative benefits of the above cost-
sharing strategies on publicly-funded prescription drug expendi-
ture plans, as to the best of our knowledge, limited observational
evidence exists within these systems regarding the impact of cost-
sharing strategies on global system expenditures [32]. In dynamic
systems that are not immune to changes in the social, demographic
and economic climate, it is difficult to assess and extrapolate the
relative impact of each cost-containment measure on pharmaceu-
tical expenditures. Though, as identified above, there are isolated
reports on the impact of copayments on individual outcomes
(effectiveness, adherence, and patient expenditure) [13,15–25,33],
studies examining the impact of these different measures at a
national plan level are lacking.
Our study has limitations. The majority of the literature
identified in the systematic review came from published and grey
literature sources. Given the dynamic and responsive nature of the
drug reimbursement systems, this may not capture the current
state of the systems. In addition, obtaining information from
experts involved in the drug plan decision-making process itself
may have resulted in biased information. However, we mitigated
this bias by accessing several sources of information and targeting
individuals within the processes who are likely to be objective
(chairs of the committees and academics publishing in this area).
Future work should focus on evaluating the ability of the
implemented tools to contain costs while optimizing clinical
benefits.
Prescription-drug insurance plans are one of the most powerful
policy levels available for both controlling expenditures in a health
system and affective compliance and management among patients.
Limiting pharmaceutical expenditures is a concern for many
countries across various geographic and health systems. There are
similarities and differences in the use of cost-containment measures
and strategies aimed at reducing physician prescribing practices
across the OECD countries. However, the potential impact of
these measures on pharmaceutical expenditures is unknown at the
health system level, despite evidence indicating that increasing
copayments for patients may negatively affect clinical outcomes for
chronic conditions. Further research is needed to determine the
best approach to constrain costs, while maintaining access to
pharmaceutical drugs.
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